secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065320
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna appoints Andrew Miller and Sravan Emany to Board; Spiegelman resigns
----------------------------------------------------------------------------

- Andrew Miller (Karuna founder) appointed Class III director; granted option valued at $262k and RSUs valued at $87.5k.
- Sravan Emany (Beam CFO) appointed Class I director and Audit Committee Chair; receives same initial equity awards.
- Daniel Spiegelman resigned Feb 24, no disagreement with company operations, policies or practices.
- Miller brings drug development experience from Karuna's $14B BMS acquisition; Emany adds capital markets and rare disease expertise.
- Both directors receive cash comp: $40k board retainer plus committee fees; equity vests over 3 years with full acceleration on change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526065320/0001193125-26-065320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526065320/kytx-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer